# Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity

> **NCT03517319** · PHASE4 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 78 (estimated)

## Conditions studied

- Spasticity as Sequela of Stroke

## Interventions

- **DRUG:** Normal Saline 0.9% 1.2 ml
- **DRUG:** Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U
- **DRUG:** Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U
- **DRUG:** Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U
- **DRUG:** Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U

## Key facts

- **NCT ID:** NCT03517319
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09-01
- **Primary completion:** 2018-05
- **Final completion:** 2018-06
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2018-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03517319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03517319, "Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03517319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*